What Moonlight AI does

Moonlight AI is a Swiss AI diagnostics company, founded in 2022 and headquartered at the Switzerland Innovation Park Basel Area - Jura in Courroux, with operational offices in Basel (engineering, ML, technical program management) and Tunis (clinical operations, data management, engineering). The company builds a computer-vision and deep-learning platform that analyzes whole slide images of hematology and cytology smears to detect genomic biomarkers and complex disease signatures directly from routine imaging, intended to triage and complement conventional molecular testing such as NGS in diagnostic laboratory workflows. Its product surface currently centers on a myelodysplastic syndrome (MDS) detection capability from peripheral blood, published in Annals of Hematology in June 2025, with planned extension to non-small cell lung cancer (NSCLC) and chronic lymphocytic leukemia (CLL). The platform is designed to integrate with diagnostic lab imaging hardware and Laboratory Information Systems via HL7/FHIR/DICOM and is being engineered for on-premises, cloud, or OEM-embedded deployment aligned with ISO 27001, HIPAA, GDPR and FDA/IVDR/CE regulatory requirements.

Moonlight AI is pre-revenue and pre-commercialization. Its economic model is planned Software as a Medical Device (SaMD) licensing integrated into lab imaging hardware and connected to LIS, with go-to-market executed through direct enterprise sales to diagnostic labs and hospitals plus an international clinical consortium that co-develops and validates the platform in real-world settings; no pricing or contract terms are publicly disclosed. The company serves three primary segments: diagnostic laboratories (the B2B buyer), and the user personas of hematologists and pathologists who consume the diagnostic insight. Four founding clinical partners — University of Basel, Universitätsspital Basel, Universitätsspital Zürich and Charité Universitätsmedizin Berlin — support the initial MDS validation, and a Tunis-based Clinical Study Manager is building additional partnerships across MENA and Europe. On May 6, 2026, the company closed a $3.3M USD seed round co-led by Lotus One Investment (Singapore), VP Venture Partners (Switzerland) and MEDIN Fund (Tunisia), with N&V Capital and existing investor QAI Ventures participating, and simultaneously reincorporated from a Swiss GmbH to a Swiss Stock Corporation (Aktiengesellschaft) to position for international commercialization.

Name

Moonlight AI

Legal name

Moonlight AI AG

Website

https://moonlight-ai.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Moonlight AI is a Swiss AI diagnostics startup that uses computer vision and deep learning on whole slide images of hematology and cytology smears to detect genomic biomarkers, serving diagnostic laboratories, hematologists, and pathologists with plans for Software as a Medical Device products across MDS, NSCLC and CLL.

Ownership category

akta.pro rank

Product category

AI Diagnostics Software

NAICS

Other Computer Related Services (541519), Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Medical Imaging AI (HDAAAEAH), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

Keywords

• AI diagnostics software
• Computational pathology
• Whole slide imaging
• Genomic biomarker detection
• Hematology image analysis

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pre-commercialization software diagnostics (planned): Company is pre-revenue and pre-commercialization. Seed funding is being used to expand the proprietary data library, team growth, and pursue regulatory approval (FDA, IVDR, CE marking) for AI-powered diagnostic software in MDS, non-small cell lung cancer, and chronic lymphocytic leukemia. Future revenue is expected from a Software as a Medical Device (SaMD) model integrated into diagnostic lab imaging hardware, but no pricing or licensing model is publicly disclosed.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Moonlight AI develops AI-powered diagnostic software that uses computer vision to detect genomic biomarkers and complex disease signatures directly from routine whole slide images of blood, bone marrow, and other cytology smears. The software integrates with diagnostic lab imaging hardware and Laboratory Information Systems to complement and triage conventional molecular testing, delivering faster turnaround times and more automated workflows for hematology and cytopathology. Validated diagnostic applications include sub-2-minute detection of myelodysplastic syndrome from peripheral blood, with ongoing extension to non-small cell lung cancer and chronic lymphocytic leukemia.

Product overview

Moonlight AI offers a single unified AI diagnostics platform — the Moonlight AI Diagnostics Platform — that converts routine microscopic imaging of hematology and cytology smears into genomic insights for hematologists and pathologists. The platform is built on a foundation of multimodal data that pairs whole slide images with genomic results, and is powered by a proprietary Moonlight AI Proprietary Cytopathology Data Library linking whole slide imaging of cytopathology samples with high-quality genomic data. On top of this core platform, validated diagnostic applications such as the MDS Detection from Peripheral Blood (AI Model) demonstrate specific clinical use cases (e.g., detecting myelodysplastic syndrome from neutrophil morphology in peripheral blood in under 2 minutes), with ongoing extension to non-small cell lung cancer and chronic lymphocytic leukemia. The platform integrates with diagnostic lab imaging hardware and Laboratory Information Systems (LIS) via HL7/FHIR to complement and triage conventional molecular testing workflows.

Differentiator

Problem solved

Functional benefit

Products and services

• Moonlight AI Diagnostics Platform AI-powered diagnostics software that uses computer vision to detect genomic biomarkers and complex disease signatures directly from routine imaging of blood, bone marrow, and other cytology smears. The platform integrates with diagnostic lab imaging hardware and Laboratory Information Systems to complement and triage conventional molecular testing such as NGS, providing faster turnaround times and more automated workflows for diagnostic laboratories, hematologists, and pathologists. It is being developed as Software as a Medical Device (SaMD) for indications including myelodysplastic syndrome (MDS), non-small cell lung cancer, and chronic lymphocytic leukemia (CLL).
• MDS Detection from Peripheral Blood (AI Model) AI-based diagnostic application that detects myelodysplastic syndrome (MDS) from neutrophil morphology in peripheral blood smears, providing a non-invasive first-line diagnostic result in under 2 minutes. It identifies sub-cellular dysplastic features too subtle for human observers, eliminating or reducing the need for invasive bone marrow biopsies in many cases and enabling faster access to genomic-guided treatment decisions for hematologists.

Quantifiable outcome

• Diagnostic results in under 2 minutes vs. 4-5 weeks for traditional MDS testing (bone marrow biopsy + genomic testing)
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered core (founding clinical research partner) and minor (ecosystem support).

• University of Baselcore (founding clinical research partner)Strategic or Co-development PartnerAcademic clinical research partner that co-authored Moonlight AI's peer-reviewed Annals of Hematology publication on detecting MDS from peripheral blood. Founder Christian Ruiz is also a Professor at the University of Basel Medical Faculty.
• Universitätsspital Baselcore (founding clinical research partner)Strategic or Co-development PartnerUniversity hospital that co-developed and validated Moonlight AI's peripheral blood MDS detection model as part of the initial four-partner consortium.
• Universitätsspital Zürichcore (founding clinical research partner)Strategic or Co-development PartnerUniversity hospital that co-developed and validated Moonlight AI's peripheral blood MDS detection model as part of the initial four-partner consortium.
• Charité Universitätsmedizin Berlincore (founding clinical research partner)Strategic or Co-development PartnerBerlin university hospital where CMO Dr. Stefan Habringer leads his own research group; co-developed and validated Moonlight AI's peripheral blood MDS detection model as part of the initial consortium.
• DayOneminor (ecosystem support)OthersSwiss digital health innovation hub listed under 'Supported by' on the Moonlight AI website, providing regional ecosystem support.
• VentureKickminor (ecosystem support)OthersSwiss startup funding program listed under 'Supported by' on the Moonlight AI website, indicating prior non-dilutive or ecosystem support.
• Basel Areaminor (ecosystem support)OthersRegional business promotion agency for the Basel area listed under 'Supported by' on the Moonlight AI website, providing regional ecosystem support.
• Jura Promotion Economiqueminor (ecosystem support)OthersJura canton economic development agency listed under 'Supported by' on the Moonlight AI website; Moonlight's HQ at Switzerland Innovation Park Basel Area - Jura is located in Courroux, Canton of Jura.
• University of Basel Startupminor (ecosystem support)OthersUniversity of Basel's startup support initiative listed under 'Supported by' on the Moonlight AI website, providing academic entrepreneurship support.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Owkin: AI biotech using multimodal patient data (including imaging and molecular) to develop diagnostic and therapeutic decision-support tools, with a strong presence in Europe. Comparable in combining imaging-derived AI with molecular insight for oncology decision support.
• Aignostics: Berlin-based AI pathology company spun out of Charit\u00e9, building foundation models for pathology image analysis and partnering with pharma and diagnostic labs. Comparable European AI-pathology peer with similar academic origins and lab-embedded go-to-market.
• Ibex Medical Analytics: Israel-based AI pathology company with multiple CE-marked and deployed products for cancer detection in routine pathology workflows. Closest pure-play peer to Moonlight's lab-embedded, image-based SaMD model for oncology diagnostics.
• Paige AI: AI-driven digital pathology platform with FDA-cleared products for prostate and breast cancer. Directly comparable to Moonlight AI as both build deep learning models that derive molecular / diagnostic insight from whole slide images and pursue SaMD clearance in oncology.
• PathAI: AI pathology company developing deep learning models on whole slide images for diagnostic and biomarker applications across oncology. Highly comparable business model: AI + pathology + clinical partnerships + pharma services, also pre-commercial / clinical-stage.
• Proscia: Digital pathology software platform with AI applications for cancer diagnosis and biomarker detection, integrating with lab imaging hardware and LIS environments. Comparable as an enterprise pathology software company with embedded AI diagnostics.

Broad incumbents

• Tempus Labs: Large US AI-driven precision medicine company combining molecular profiling, imaging and clinical data for oncology decision support. Comparable end goal (imaging + genomics for cancer) but much broader portfolio and substantially more capital than Moonlight AI.
• DeepHealth (RadNet): Subsidiary of RadNet applying AI to medical imaging and diagnostics, with FDA-cleared products and broad imaging footprint. Comparable as an AI imaging diagnostics platform, though focused on radiology rather than pathology/hematology.
• Lunit: South Korea-based AI medical imaging company with cleared products for chest X-ray, mammography and pathology biomarker prediction (e.g., Lunit SCOPE). Comparable in applying deep learning to histology/biomarker prediction, though broader in scope and modality coverage.

Emerging players

• Stratipath: Stockholm-based AI precision diagnostics company focused on AI-based prognostic and predictive biomarker profiling from routine histopathology images. Comparable as a European SaMD peer using image-only AI to derive molecular-grade insight for oncology treatment decisions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/moonlight-ai

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moonlight AI